Alpha Tau Medical (DRTS) said Monday the US Food and Drug Administration approved an investigational device exemption supplement for its Alpha DaRT radiation therapy.
The supplement allows for the expansion of the study examining the combination of Alpha DaRT and first-line chemotherapy to include both newly diagnosed metastatic and locally advanced pancreatic cancer patients, increasing the total number of patients to 30 across two cohorts, according to the company.
Shares of Alpha Tau Medical were down 1.6% in recent trading.
Price: 3.64, Change: -0.06, Percent Change: -1.62
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.